Apr 24 |
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
|
Apr 10 |
Kiromic BioPharma files to withdraw registration statement
|
Apr 2 |
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
|
Mar 19 |
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
|
Mar 8 |
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
|
Mar 5 |
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
|
Mar 1 |
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
|
Feb 28 |
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
|
Feb 14 |
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
|
Jan 29 |
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
|